is tirzepatide discontinued for Weight Loss sustainable wellness goals. FDA says shortage of GLP-1

However, realistic expectations matter: semaglutide monotherapy produces an average 15-22% body weight reduction over 68 weeks in clinical trials, which is substantial and sustainable when combined with lifestyle changes

Building on the success of the original CoolSculpting technology, Elite introduces redesigned applicators and enhanced cooling systems that treat more tissue faster and more comfortablydelivering better, more consistent outcomes

Patients who adopt these habits alongside semaglutide treatment often experience more sustainable weight loss results

The MHRA-approved prescribing information confirms that the abdomen, thigh, and upper arm are all suitable injection sites, and you should follow the specific guidance in the Patient Information Leaflet for your medication

Semaglutide acts primarily on the GLP-1 receptor, helping regulate appetite, stabilize blood sugar, and support steady fat loss